Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10096-020-04104-2 http://scihub22266oqcxt.onion/10.1007/s10096-020-04104-2 33179133!7657073!33179133     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Microbiol+Infect+Dis 2021 ; 40 (2): 361-371 Nephropedia Template TP {{tp|p=33179133|t=2021. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France |pdf=|usr=}}{{33179133}} gab.com Text Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France JO: Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33179133 #FOAvip An indirect in-house immunofluorescent assay was developed in order to assess the serological status of COVID-19 patients in Marseille, France. Performance of IFA was compared to a commercial ELISA IgG kit. We tested 888 RT-qPCR-confirmed COVID-19 patients (1302 serum samples) and 350 controls including 200 sera collected before the pandemic, 64 sera known to be associated with nonspecific serological interference, 36 sera from non-coronavirus pneumonia and 50 sera from patient with other common coronavirus to elicit false-positive serology. Incorporating an inactivated clinical SARS-CoV-2 isolate as the antigen, the specificity of the assay was measured as 100% for IgA titre >/= 1:200, 98.6% for IgM titre >/= 1:200 and 96.3% for IgG titre >/= 1:100 after testing a series of negative controls. IFA presented substantial agreement (86%) with ELISA EUROIMMUN SARS-CoV-2 IgG kit (Cohen's Kappa = 0.61). The presence of antibodies was then measured at 3% before a 5-day evolution up to 47% after more than 15 days of evolution. We observed that the rates of seropositivity as well as the titre of specific antibodies were both significantly higher in patients with a poor clinical outcome than in patients with a favourable evolution. These data, which have to be integrated into the ongoing understanding of the immunological phase of the infection, suggest that detection anti-SARS-CoV-2 antibodies is useful as a marker associated with COVID-19 severity. The IFA assay reported here is useful for monitoring SARS-CoV-2 exposure at the individual and population levels. Twit Text FOAVip Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France ????Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33179133 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33179133 #FOAvip English Wikipedia <ref>{{Cite pmid|33179133}}</ref> Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France #MMPMID33179133 Edouard S; Colson P; Melenotte C; Di Pinto F; Thomas L; La Scola B; Million M; Tissot-Dupont H; Gautret P; Stein A; Brouqui P; Parola P; Lagier JC; Raoult D; Drancourt M Eur J Clin Microbiol Infect Dis 2021[Feb]; 40 (2): 361-371 PMID33179133show ga An indirect in-house immunofluorescent assay was developed in order to assess the serological status of COVID-19 patients in Marseille, France. Performance of IFA was compared to a commercial ELISA IgG kit. We tested 888 RT-qPCR-confirmed COVID-19 patients (1302 serum samples) and 350 controls including 200 sera collected before the pandemic, 64 sera known to be associated with nonspecific serological interference, 36 sera from non-coronavirus pneumonia and 50 sera from patient with other common coronavirus to elicit false-positive serology. Incorporating an inactivated clinical SARS-CoV-2 isolate as the antigen, the specificity of the assay was measured as 100% for IgA titre >/= 1:200, 98.6% for IgM titre >/= 1:200 and 96.3% for IgG titre >/= 1:100 after testing a series of negative controls. IFA presented substantial agreement (86%) with ELISA EUROIMMUN SARS-CoV-2 IgG kit (Cohen's Kappa = 0.61). The presence of antibodies was then measured at 3% before a 5-day evolution up to 47% after more than 15 days of evolution. We observed that the rates of seropositivity as well as the titre of specific antibodies were both significantly higher in patients with a poor clinical outcome than in patients with a favourable evolution. These data, which have to be integrated into the ongoing understanding of the immunological phase of the infection, suggest that detection anti-SARS-CoV-2 antibodies is useful as a marker associated with COVID-19 severity. The IFA assay reported here is useful for monitoring SARS-CoV-2 exposure at the individual and population levels. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/*blood[MESH] |COVID-19/*diagnosis/immunology[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Fluorescent Antibody Technique, Indirect/*methods[MESH] |Humans[MESH] |Immunoglobulin G/blood[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology[MESH]Evaluating the serological status of COVID-19 patients using an indire(epmc).pdf DeepDyve Pubget Overpricing